Woman standing in front of injection devices manufacturing area

Bespak are the drug delivery device experts, now part of Recipharm

Operational impact of COVID-19

Products

For customers requiring device technology to deliver a drug, we can offer a variety of proprietary technologies for multiple routes of administration, including inhalation, injectable and intranasal.

View Our Products

Services

From innovation, development and clinical supply to industrialisation and high volume manufacturing of drug delivery devices.

View Our Services

Sustainability and innovation in the complex combination therapy sector

26th March 2020 Read more

Recipharm supports FDA approval of Perrigo’s AB-rated generic product

11th March 2020 Read more

Bespak becomes part of the Recipharm Group

3rd March 2020 Read more

VapourSoft® Development Agreement signed with Regeneron

18th October 2019 Read more

Our range of drug delivery devices specifically targeting high-viscosity drugs and higher delivery volumes

9th September 2019 Read more

Syrina® AS: A readily available, highly flexible device

13th May 2019 Read more

Compliant packaging for global distribution

12th May 2019 Read more

BK640: Integrated Dose Counting Actuator

7th May 2019 Read more

Chiesi NEXTHaler®

11th September 2015

Chiesi’s proprietary dry powder inhaler device – the NEXTHaler™, was successfully launched in the EU, in 2013.

Over 20 years ago we were selected by GlaxoSmithKline (GSK) to be their original partner in taking the initial Diskus® Dry Powder Inhaler (DPI) concept from clinical stage, right through to industrial realisation, and subsequent high volume commercial supply.

Syrina® AR: Our 2ml auto-injector with automatic needle retraction

26th April 2014 Read more